Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Abingdon Health progresses at-home STD test programme
(Sharecast News) - Abingdon Health updated the market on the development of self-tests for sexually transmitted diseases (STDs) on Monday, announcing the completion of the 'design freeze' stage for four key tests in collaboration with Devyn. The AIM-traded firm said the tests, covering HIV, hepatitis B, hepatitis C and syphilis, were developed under a CDMO contract with Devyn's subsidiary 'Find Out From Home'.
It said the development was part of a broader strategic partnership between Abingdon Health and Find Out, formalised through a service for equity agreement.
Under the agreement, Abingdon would continue to offer regulatory and technical transfer services, and also take a significant minority equity stake in Find Out.
As the exclusive manufacturer and regulatory partner for the products, Abingdon Health said it would lead distribution in the UK and Europe.
The initiative could tap into a growing demand for STD testing, with the global market expected to reach $145bn by 2035, driven by increasing STD cases among young adults and a lack of awareness about safe sex practices.
Abingdon said its chief executive officer Chris Yates would join the board of Find Out, further cementing the strategic alignment between the two entities.
"We are delighted to announce the strategic partnership with Find Out From Home," said chief executive officer Chris Yates.
"We have been working with the team at Find Out for the past year and are pleased that the initial set of four STD lateral flow tests have now reached design freeze."
Yates said the company was looking forward to deepening its partnership with Find Out, and ultimately launching the rapid STD tests into the European market.
"We believe there is a significant unmet need for accurate, user-friendly STD lateral flow tests and this partnership underlines our approach in supporting customers on bringing innovative lateral flow tests from "idea to commercial success."
At 1500 GMT, shares in Abingdon Health were up 8.11% at 10p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
